Sales & Marketing News | pharmaphorum

News

Hernexeos box, two pills, and pill bottle

Boehringer gets FDA's second 'national priority' approval

Boehringer Ingelheim's lung cancer drug Hernexeos has become the second medicine approved after an FDA national priority review.

News

Asahi Kasei buys antiviral firm Aicuris for €780m

Asahi Kasei has agreed to buy Germany's Aicuris for around $920m, adding an antiviral drug it hopes will help drive its 2030 pharma sales to $1.9bn.

News

Changes at the top of Sarepta, Alkermes, as CEOs depart

Two long-serving pharma CEOs have announced their departures, as Sarepta's Doug Ingram and Alkermes' Richard Pops announce their retirement.

News

Black background scattered with red 'SALE' tickets

Novo Nordisk to cut GLP-1 prices in tough US market

Novo Nordisk has turned to pricing as a means to shore up its position in the increasingly competitive market for GLP-1 agonist therapies in the US.

News

MSD splits pharma business, hiving off oncology

MSD is separating its cancer and non-cancer pharma operations as it prepares for the looming loss of patent protection for $31bn blockbuster Keytruda.

News

FDA clears first all-oral combo for first-line CLL treatment

AstraZeneca's Calquence and AbbVie/Roche's Venclexta have become the first all-oral, fixed-duration regimen for newly-diagnosed CLL.

Boehringer gets FDA's second 'national priority' approval

Asahi Kasei buys antiviral firm Aicuris for €780m

Changes at the top of Sarepta, Alkermes, as CEOs depart

Novo Nordisk to cut GLP-1 prices in tough US market

MSD splits pharma business, hiving off oncology

FDA clears first all-oral combo for first-line CLL treatment

FDA issues warning letters to five unapproved GLP-1 websites

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks